|
86 Companies |
|
134 Products |
|
134 Products |
|
85 Mechanisms of Action |
|
5 Trials |
|
1881 News |
|
| «12345678910111213...3738» |
- Trial completion: Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=1, Completed, Sponsor: University of Manchester
Recruiting --> Completed
- Trial termination: The Topical Niacin Skin Flush Test in First Episode Psychosis (clinicaltrials.gov) - Jul 29, 2016
P3, N=107, Terminated, Sponsor: Nova Scotia Health Authority
Recruiting --> Completed Recruiting --> Terminated; Unable to secure funding for second phase of study (i.e., niacin skin flush test in early psychosis patients).
- Trial completion: Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS) (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=60, Completed, Sponsor: Chiang Mai University
Recruiting --> Terminated; Unable to secure funding for second phase of study (i.e., niacin skin flush test in early psychosis patients). Recruiting --> Completed
- Trial completion: Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=80, Completed, Sponsor: Chiang Mai University
Recruiting --> Completed Recruiting --> Completed
- Enrollment open, Trial initiation date: Phase II Motivational Interviewing: An Experiential Online Training Tool (clinicaltrials.gov) - Jul 28, 2016
P2, N=3780, Recruiting, Sponsor: Center for Social Innovation, Massachusetts
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Mar 2016
- Enrollment closed, Trial primary completion date: Fingolimod in Schizophrenia Patients (clinicaltrials.gov) - Jul 28, 2016
P2, N=40, Active, not recruiting, Sponsor: Indiana University
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016
- Enrollment change, Trial initiation date, Trial withdrawal: Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients (clinicaltrials.gov) - Jul 21, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016 N=50 --> 0 | Initiation date: Jun 2016 --> Jun 2013 | Not yet recruiting --> Withdrawn
- metformin / Generic mfg.
Trial primary completion date: Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness (clinicaltrials.gov) - Jul 20, 2016
P4, N=24, Recruiting, Sponsor: Centre for Addiction and Mental Health
N=50 --> 0 | Initiation date: Jun 2016 --> Jun 2013 | Not yet recruiting --> Withdrawn Trial primary completion date: Jun 2016 --> Dec 2016
- || valacyclovir / Generic mfg.
Trial primary completion date: A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (clinicaltrials.gov) - Jul 19, 2016
P2, N=175, Recruiting, Sponsor: Indiana University
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial suspension, Trial primary completion date: Linagliptin in Schizophrenia Patients (clinicaltrials.gov) - Jul 19, 2016
P1, N=5, Suspended, Sponsor: Monash University
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2016
- Enrollment closed: Probiotics to Prevent Relapse After Hospitalization for Mania (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=66, Active, not recruiting, Sponsor: Sheppard Pratt Health System
Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2016 Enrolling by invitation --> Active, not recruiting
- ||||||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
Trial completion: An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) (clinicaltrials.gov) - Jul 15, 2016
P3, N=291, Completed, Sponsor: Alkermes, Inc.
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Completed
- Trial completion, Enrollment change: Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism (clinicaltrials.gov) - Jul 14, 2016
P2, N=20, Completed, Sponsor: Yale University
Enrolling by invitation --> Completed Active, not recruiting --> Completed | N=46 --> 20
- Enrollment closed: Cognitive Remediation for First Episode of Psychosis Patients (clinicaltrials.gov) - Jul 6, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: University of Manchester
Active, not recruiting --> Completed | N=46 --> 20 Recruiting --> Active, not recruiting
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion, Trial primary completion date: Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress (clinicaltrials.gov) - Jul 5, 2016
P3, N=837, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Apr 2016
- Trial primary completion date: Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=60, Recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Apr 2016 Trial primary completion date: Feb 2016 --> Dec 2016
- minocycline / Generic mfg.
Trial completion, Trial primary completion date: MINOS: Minocycline for Schizophrenia (clinicaltrials.gov) - Jun 30, 2016
P4, N=150, Completed, Sponsor: Addis Ababa University
Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> May 2016
- Trial completion, Enrollment change, Trial primary completion date: Effects of a Walking Program in People With Mental Disorders (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=135, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> May 2016 Recruiting --> Completed | N=100 --> 135 | Trial primary completion date: Dec 2015 --> Jun 2016
- Enrollment closed: Padres Efectivos (Parent Activation): Skills Latina Mothers Use to Get Healthcare for Their Children (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=302, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=100 --> 135 | Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Enrollment change, Trial termination: Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia (clinicaltrials.gov) - Jun 23, 2016
P1/2, N=18, Terminated, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Active, not recruiting N=72 --> 18 | Recruiting --> Terminated
- Trial completion, Trial primary completion date: Lifestyle Intervention for Diabetes and Weight Management in Psychosis (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=120, Completed, Sponsor: Centre for Addiction and Mental Health
N=72 --> 18 | Recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015
- AVL-3288 / Anvyl
Trial primary completion date: Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects (clinicaltrials.gov) - Jun 16, 2016
P1, N=80, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015 Trial primary completion date: May 2016 --> May 2017
- Trial completion: Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM) (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=486, Completed, Sponsor: Wolfgang Gaebel, Professor
Trial primary completion date: May 2016 --> May 2017 Active, not recruiting --> Completed
- |||| osoresnontrine (BI 409306) / Boehringer Ingelheim
Trial completion: A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. (clinicaltrials.gov) - Jun 15, 2016
P2, N=518, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Trial primary completion date: Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma (clinicaltrials.gov) - Jun 13, 2016
P2, N=57, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Feb 2017
- ||||||| iloperidone / Generic mfg.
Trial completion, Trial primary completion date: REPRIEVE: Relapse Prevention Study in Patients With Schizophrenia (clinicaltrials.gov) - Jun 13, 2016
P3, N=303, Completed, Sponsor: Vanda Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2015
- aripiprazole / Generic mfg., amisulpride / Generic mfg.
Trial completion: Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS) (clinicaltrials.gov) - May 27, 2016
P=N/A, N=136, Completed, Sponsor: University of Copenhagen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2015 Active, not recruiting --> Completed
- ||| aripiprazole / Generic mfg.
Trial completion, Trial primary completion date: Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (clinicaltrials.gov) - May 25, 2016
P=N/A, N=83, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Feb 2016
- | Enrollment closed, Trial primary completion date, Head-to-Head: TaSCS: Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (clinicaltrials.gov) - May 24, 2016
P3, N=324, Active, not recruiting, Sponsor: University of Cape Town
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017
- Trial primary completion date: Cognitive Remediation of Schizophrenia in a Community Mental Health Setting (clinicaltrials.gov) - May 17, 2016
P=N/A, N=120, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017 Trial primary completion date: Nov 2015 --> Jun 2016
- Enrollment closed, Trial primary completion date: CAST: Optimizing Cognitive Remediation Outcomes in Schizophrenia (clinicaltrials.gov) - May 17, 2016
P=N/A, N=160, Active, not recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Nov 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2016
- Enrollment closed: Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis (clinicaltrials.gov) - May 17, 2016
P1/2, N=100, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: Adaptive Treatment for Adolescent Cannabis Use Disorders (clinicaltrials.gov) - May 14, 2016
P=N/A, N=172, Active, not recruiting, Sponsor: University of Connecticut Health Center
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> Jul 2016
- Trial initiation date, Trial primary completion date: Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients (clinicaltrials.gov) - May 13, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Feb 2016 --> Jul 2016 Initiation date: Sep 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017
- betahistine / Generic mfg.
Trial primary completion date: Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain (clinicaltrials.gov) - May 6, 2016
P2, N=40, Recruiting, Sponsor: Nathan Kline Institute for Psychiatric Research
Initiation date: Sep 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Apr 2012 --> Dec 2016
- || Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial primary completion date: ReLiAM: Real Life Assessment of Abilify Maintena (clinicaltrials.gov) - May 5, 2016
P=N/A, N=252, Recruiting, Sponsor: Lundbeck Canada Inc.
Trial primary completion date: Apr 2012 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2016
- ||||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial completion: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 3, 2016
P3, N=767, Completed, Sponsor: FORUM Pharmaceuticals Inc
Trial primary completion date: May 2016 --> Aug 2016 Active, not recruiting --> Completed
- ||||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial completion: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 3, 2016
P3, N=753, Completed, Sponsor: FORUM Pharmaceuticals Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Trial completion, Enrollment change, Trial primary completion date: A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 3, 2016
P3, N=830, Completed, Sponsor: FORUM Pharmaceuticals Inc
Active, not recruiting --> Completed Suspended --> Completed | N=1050 --> 830 | Trial primary completion date: Sep 2016 --> Oct 2015
- ||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes, Aristada two-month (aripiprazole lauroxil XR) / Alkermes
Trial completion, Trial primary completion date: An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia (clinicaltrials.gov) - May 3, 2016
P1, N=140, Completed, Sponsor: Alkermes, Inc.
Suspended --> Completed | N=1050 --> 830 | Trial primary completion date: Sep 2016 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016
- JNJ-39393406 / J&J
Trial primary completion date: Novel Smoking Cessation Drug for Schizophrenia (clinicaltrials.gov) - May 3, 2016
P2, N=60, Recruiting, Sponsor: K.N. Roy Chengappa
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016 Trial primary completion date: Sep 2016 --> Apr 2017
- Enrollment closed, Enrollment change: PRIN2014: Factors Influencing Social Functioning of People With Schizophrenia (clinicaltrials.gov) - May 3, 2016
P=N/A, N=587, Active, not recruiting, Sponsor: Second University of Naples
Trial primary completion date: Sep 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=760 --> 587
- clozapine / Generic mfg.
Trial primary completion date: Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients (clinicaltrials.gov) - Apr 26, 2016
P4, N=20, Recruiting, Sponsor: Tirat Carmel Mental Health Center
Recruiting --> Active, not recruiting | N=760 --> 587 Trial primary completion date: May 2015 --> Nov 2016
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (clinicaltrials.gov) - Apr 22, 2016
P4, N=75, Recruiting, Sponsor: New York State Psychiatric Institute
Trial primary completion date: May 2015 --> Nov 2016 N=50 --> 75
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change, Trial primary completion date: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=450, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=50 --> 75 N=360 --> 450 | Trial primary completion date: Aug 2017 --> Feb 2018
- Enrollment closed, IO biomarker, Immunomodulating: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=80, Active, not recruiting, Sponsor: University of Pittsburgh
N=360 --> 450 | Trial primary completion date: Aug 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- Trial primary completion date: Yoga as Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=286, Active, not recruiting, Sponsor: Dr. Ram Manohar Lohia Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2015
- ||| APN1125 / CoMentis, Alpharmagen
Trial completion, Trial primary completion date: Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects (clinicaltrials.gov) - Apr 8, 2016
P1, N=58, Completed, Sponsor: CoMentis
Trial primary completion date: Dec 2015 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2015
- ||| omega-3 ethylester concentrate / Generic mfg.
Enrollment change: Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia (clinicaltrials.gov) - Apr 4, 2016
P4, N=65, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Nov 2015 N=40 --> 65
- Trial completion, Trial primary completion date: DAAOI-1 Treatment for Treatment-resistant Schizophrenia (clinicaltrials.gov) - Mar 31, 2016
P2, N=60, Completed, Sponsor: China Medical University Hospital
N=40 --> 65 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014